-
Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Saturday, June 23, 2018 - 10:21am | 524Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) — a clinical-stage biopharmaceutical company focused on bringing to market advanced products based on the potential of gene therapy — have been highly volatile, but the company has a "clear path" toward commercialization,...
-
The BLUE And The BOLD; Analyst Suggests Pair Trade Ahead Of Year-End Catalysts
Monday, October 16, 2017 - 1:30pm | 450Read More...Evercore ISI on Monday outlined a pair trade in the biotech sector, with the firm upgrading shares of bluebird bio Inc (NASDAQ: BLUE), while simultaneously downgrading those of Audentes Therapeutics Inc (NASDAQ: BOLD). The firm upgraded shares of Bluebird from In-Line to Outperform, while it...
